A Study to Evaluate the Safety and Tolerability of SX-682 in Combination With Nivolumab as a Maintenance Therapy in Patients With Metastatic Pancreatic Ductal Adenocarcinoma
An Open-label Phase 1 Study to Evaluate the Safety and Tolerability of SX-682 in Combination With Nivolumab as a Maintenance Therapy in Patients With Metastatic Pancreatic Ductal Adenocarcinoma
Sponsor: Bristol-Myers Squibb
Listed as NCT04477343, this PHASE1 trial focuses on Pancreatic Cancer and Pancreatic Ductal Adenocarcinoma and remains actively recruiting participants. Sponsored by Bristol-Myers Squibb, it has been updated 15 times since 2020, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
15 versions recorded-
Jul 2025 — Present [monthly]
Recruiting PHASE1
-
Jun 2025 — Jul 2025 [monthly]
Recruiting PHASE1
-
Apr 2025 — Jun 2025 [monthly]
Recruiting PHASE1
Status: Suspended → Recruiting
-
Mar 2025 — Apr 2025 [monthly]
Suspended PHASE1
Status: Recruiting → Suspended
-
Sep 2024 — Mar 2025 [monthly]
Recruiting PHASE1
▶ Show 10 earlier versions
-
Jul 2024 — Sep 2024 [monthly]
Recruiting PHASE1
-
Mar 2024 — Jul 2024 [monthly]
Recruiting PHASE1
-
Sep 2023 — Mar 2024 [monthly]
Recruiting PHASE1
-
Feb 2023 — Sep 2023 [monthly]
Recruiting PHASE1
-
Dec 2022 — Feb 2023 [monthly]
Recruiting PHASE1
-
Sep 2022 — Dec 2022 [monthly]
Recruiting PHASE1
-
Jan 2022 — Sep 2022 [monthly]
Recruiting PHASE1
-
Jan 2021 — Jan 2022 [monthly]
Recruiting PHASE1
-
Dec 2020 — Jan 2021 [monthly]
Recruiting PHASE1
Status: Not Yet Recruiting → Recruiting
-
Aug 2020 — Dec 2020 [monthly]
Not Yet Recruiting PHASE1
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Bristol-Myers Squibb
- Syntrix Biosystems, Inc.
- University of Rochester
For direct contact, visit the study record on ClinicalTrials.gov .